Journal Of Cellular Physiology 2015-07-01

Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease.

Hany E S Marei, Samah Lashen, Amany Farag, Asmaa Althani, Nahla Afifi, Abd-Elmaksoud A, Shaymaa Rezk, Roberto Pallini, Patrizia Casalbore, Carlo Cenciarelli

Index: J. Cell Physiol. 230(7) , 1614-29, (2015)

Full Text: HTML

Abstract

Parkinson's disease (PD) is a neurological disorder characterized by the loss of midbrain dopaminergic (DA) neurons. Neural stem cells (NSCs) are multipotent stem cells that are capable of differentiating into different neuronal and glial elements. The production of DA neurons from NSCs could potentially alleviate behavioral deficits in Parkinsonian patients; timely intervention with NSCs might provide a therapeutic strategy for PD. We have isolated and generated highly enriched cultures of neural stem/progenitor cells from the human olfactory bulb (OB). If NSCs can be obtained from OB, it would alleviate ethical concerns associated with the use of embryonic tissue, and provide an easily accessible cell source that would preclude the need for invasive brain surgery. Following isolation and culture, olfactory bulb neural stem cells (OBNSCs) were genetically engineered to express hNGF and GFP. The hNFG-GFP-OBNSCs were transplanted into the striatum of 6-hydroxydopamin (6-OHDA) Parkinsonian rats. The grafted cells survived in the lesion environment for more than eight weeks after implantation with no tumor formation. The grafted cells differentiated in vivo into oligodendrocyte-like (25 ± 2.88%), neuron-like (52.63 ± 4.16%), and astrocyte -like (22.36 ± 1.56%) lineages, which we differentiated based on morphological and immunohistochemical criteria. Transplanted rats exhibited a significant partial correction in stepping and placing in non-pharmacological behavioral tests, pole and rotarod tests. Taken together, our data encourage further investigations of the possible use of OBNSCs as a promising cell-based therapeutic strategy for Parkinson's disease.© 2014 Wiley Periodicals, Inc.

Related Compounds

Structure Name/CAS No. Articles
Cyclosporin A Structure Cyclosporin A
CAS:59865-13-3
Fluorescein Structure Fluorescein
CAS:2321-07-5
Methyl isothiocyanate Structure Methyl isothiocyanate
CAS:556-61-6
H-Dab.HCl Structure H-Dab.HCl
CAS:1482-98-0
Retinoic acid Structure Retinoic acid
CAS:302-79-4
Geneticin Structure Geneticin
CAS:108321-42-2
4',6-Diamidino-2-phenylindole dihydrochloride Structure 4',6-Diamidino-2-phenylindole dihydrochloride
CAS:28718-90-3
DL-Tyrosine Structure DL-Tyrosine
CAS:556-03-6
(+/-)-2-HYDROXYTRIDECANOICACID Structure (+/-)-2-HYDROXYTRIDECANOICACID
CAS:100828-16-8
Oxidopamine hydrochloride Structure Oxidopamine hydrochloride
CAS:28094-15-7